[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1303 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 1303

To direct the Comptroller General of the United States to evaluate and 
      report on the inpatient and outpatient treatment capacity, 
             availability, and needs of the United States.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2019

  Mr. Foster introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
 Natural Resources, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To direct the Comptroller General of the United States to evaluate and 
      report on the inpatient and outpatient treatment capacity, 
             availability, and needs of the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Examining Opioid Treatment 
Infrastructure Act of 2019''.

SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE.

    Not later than 24 months after the date of enactment of this Act, 
the Comptroller General of the United States shall initiate an 
evaluation of, and submit to Congress a report on, the inpatient and 
outpatient treatment capacity, availability, and needs of the United 
States, including, to the extent data are available--
            (1) the capacity of acute residential or inpatient 
        detoxification programs;
            (2) the capacity of inpatient clinical stabilization 
        programs, transitional residential support services, and 
        residential rehabilitation programs;
            (3) the capacity of demographic specific residential or 
        inpatient treatment programs, such as those designed for 
        pregnant women or adolescents;
            (4) geographical differences of the availability of 
        residential and outpatient treatment and recovery options for 
        substance use disorders across the continuum of care;
            (5) the availability of residential and outpatient 
        treatment programs that offer treatment options based on 
        reliable scientific evidence of efficacy for the treatment of 
        substance use disorders, including the use of Food and Drug 
        Administration-approved medicines and evidence-based 
        nonpharmacological therapies;
            (6) the number of patients in residential and specialty 
        outpatient treatment services for substance use disorders;
            (7) an assessment of the need for residential and 
        outpatient treatment for substance use disorders across the 
        continuum of care;
            (8) the availability of residential and outpatient 
        treatment programs to American Indians and Alaska Natives 
        through an Indian health program (as defined by section 4 of 
        the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
            (9) the barriers (including technological barriers) at the 
        Federal, State, and local levels to real-time reporting of de-
        identified information on drug overdoses and ways to overcome 
        such barriers.
                                 <all>